Cosmos Health Inc. (COSM) · Oct 9, 2026 · Earnings

Cosmos Health earnings miss revenue estimates despite $90M outlook

Miss — Q3 revenue ~$17.4M vs ~$21.3M published consensus

Cosmos Health’s preliminary Q3 earnings show record revenue growth, but sales fall short of published estimates while its full-year outlook remains intact.

Cosmos Health is scaling a vertically integrated healthcare platform across contract manufacturing, pharmaceutical distribution, proprietary brands and a newer U.S. commercialization push. Its latest quarterly filing shows continued top-line expansion, but the available published Q3 revenue expectation was materially higher than the preliminary result. The company was also still loss-making and cash-burning through the first half of 2026, making the quality and conversion of this growth important.

Revenue202420252026 preliminary / outlookChange
Q3$12.4M$17.1M~$17.4M+2% YoY; +40% vs. 2024 (Revenue table)
Nine months$40.2M$45.6M~$54.3M+19% YoY; +35% vs. 2024 (Revenue table)
Full year$54.4M$65.3MOver $90M outlook~+38% expected YoY (Revenue table)

The quarter was operationally positive but financially below the bar. Preliminary Q3 revenue reached a company record of approximately $17.4 million. That is still growth against a difficult prior-year comparison, but it sits about 18% below the available published consensus of roughly $21.3 million, making this a revenue miss rather than a clean beat.

The underlying growth story remains broad, not dependent on one product. Management says contract manufacturing, pharmaceutical distribution and proprietary brands all contributed, with Cana’s production pipeline above 32.7 million units and CosmoFarm serving more than 1,500 pharmacies. 〔0〕 That supports the idea that the platform is expanding across multiple engines, while the filing’s preliminary and unaudited status means the reported number is not yet final.

The full-year target is preserved, but the Q4 burden is now substantial. Nine-month revenue of about $54.3 million is already 83% of 2025’s full-year record, yet exceeding $90 million requires more than $35.7 million in Q4—roughly double the preliminary Q3 run rate. The company reaffirmed the target and expects its strongest quarter ever. The outlook therefore avoids a guidance cut, but it depends heavily on contract-manufacturing orders, seasonal distribution and the still-developing U.S. sales ramp.

Bottom line: The business is still growing across its core segments, but Q3 sales missed the market’s available expectation by a wide margin. Reaffirmed full-year guidance keeps the expansion story alive; it does not erase the need for a much stronger fourth quarter.

What to watch next

Complete Q3 results in the September 30 10-Q

Original filing on SEC EDGAR

More Cosmos Health Inc. news

Cosmos Health earnings miss revenue estimates despite $90M outlook | COSM Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.